Open access
Open access
Powered by Google Translator Translator

Geriatrics

RCT: Metal pins no better than traditional plaster cast for a broken wrist.

21 Jan, 2022 | 09:51h | UTC

News Release: Metal pins no better than traditional plaster cast for a broken wrist – BMJ

Original Study: Surgical fixation with K-wires versus casting in adults with fracture of distal radius: DRAFFT2 multicentre randomised clinical trial – The BMJ

Commentary: Wrist fractures: study compares casting to surgical fixation – MedicalResearch.com

 

Commentary on Twitter

 


Systematic Review: In people with Alzheimer’s disease and vascular dementia with agitation and psychosis, atypical antipsychotics probably reduce agitation slightly (moderate‐certainty evidence) but probably have a negligible effect on psychosis or risk of any adverse event.

21 Jan, 2022 | 09:50h | UTC

Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia – Cochrane Library

Summary: Do antipsychotic medicines reduce  agitated behaviour and psychotic symptoms in people with Alzheimer’s disease and vascular dementia? – Cochrane Library

 


Cluster Randomized Trial: A multifactorial falls prevention program in UK care homes reduced fall rates among older people and was cost effective.

21 Jan, 2022 | 09:21h | UTC

Multifactorial falls prevention programme compared with usual care in UK care homes for older people: multicentre cluster randomised controlled trial with economic evaluation – The BMJ

News Release: Falls in care homes can be significantly reduced with intervention, says new study – University of Nottingham

 

Commentary on Twitter

 


Study shows that the retinal age gap might be a potential biomarker of aging linked to increased mortality risk.

20 Jan, 2022 | 09:04h | UTC

Retinal age gap as a predictive biomarker for mortality risk – British Journal of Ophthalmology (link to abstract – $ for full-text)

News Release: Difference between retina’s biological age and person’s real age linked to heightened death risk – BMJ

 

Commentary on Twitter

 


Cohort Study: Factors associated with 10-year declines in physical health and function among women during midlife.

19 Jan, 2022 | 08:29h | UTC

Factors Associated With 10-Year Declines in Physical Health and Function Among Women During Midlife – JAMA Network Open

Commentary: Four Factors in Midlife Predict a Healthy Old Age for Women – HealthDay

 


Perspective | Post-acute neurological consequences of COVID-19: an unequal burden – “COVID-19 and its neurological consequences particularly burden marginalized communities, and so can only be effectively treated by advancing health equity”.

18 Jan, 2022 | 09:44h | UTC

Post-acute neurological consequences of COVID-19: an unequal burden – Nature Medicine

 


Global, regional, and national burdens of hip osteoarthritis from 1990 to 2019: estimates from the 2019 Global Burden of Disease Study.

18 Jan, 2022 | 09:27h | UTC

Global, regional, and national burdens of hip osteoarthritis from 1990 to 2019: estimates from the 2019 Global Burden of Disease Study – Arthritis Research & Therapy

 


RCT: Oral Vitamin D supplementation (60.000 IU per month) did not reduce mortality in patients 60 years or older (unscreened individuals in Australia, many without insufficiency, average 30ng/mL). Exploratory analyses pointed towards an increased risk of death from cancer.

16 Jan, 2022 | 23:13h | UTC

The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

Related:

Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention

Association between vitamin D supplementation and mortality: systematic review and meta-analysis – The BMJ

USPSTF Draft Statement: Insufficient evidence to recommend multivitamin supplements for the prevention of CVD or cancer. The statement also recommends against the use of beta-carotene (increases risk of CVD mortality and lung cancer) or vitamin E (clear evidence of no benefit)

Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases

Research: Circulating vitamin D concentration and risk of seven cancers

Research: Vitamin D and risk of total and site specific cancers

 


RCT: Vitamin D supplementation is not beneficial for the prevention of cardiovascular disease and cancer.

16 Jan, 2022 | 23:11h | UTC

Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial-a randomized controlled trial – American Journal of Clinical Nutrition

News Release: Five years of high-dose vitamin D did not affect incidence of cardiovascular disease or cancer – University of Eastern Finland

Related:

Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention

Association between vitamin D supplementation and mortality: systematic review and meta-analysis – The BMJ

USPSTF Draft Statement: Insufficient evidence to recommend multivitamin supplements for the prevention of CVD or cancer. The statement also recommends against the use of beta-carotene (increases risk of CVD mortality and lung cancer) or vitamin E (clear evidence of no benefit)

Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases

Research: Circulating vitamin D concentration and risk of seven cancers

Research: Vitamin D and risk of total and site specific cancers

 


Perspective: Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio, not age.

16 Jan, 2022 | 22:53h | UTC

Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio, not age – Family Medicine and Community Health

Commentaries:

Researchers urge: ‘Prescribe aspirin based on benefit-to-risk not age’ – Florida Atlantic University

Preventive Aspirin Should Be Based on Benefit, Not Age – HealthDay

Related: USPSTF draft statement revises previous guidance and now recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults aged 60 years or older.

 


Cluster randomized trial: no added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis.

16 Jan, 2022 | 22:59h | UTC

No added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis: a cluster randomised trial – Arthritis & Rheumatism

 


Analysis: Sarcopenia: early prevention or overdiagnosis?

16 Jan, 2022 | 22:48h | UTC

Sarcopenia: early prevention or overdiagnosis? – The BMJ

Related: Overdiagnosis: it’s official – the term is now included in the medical subject headings (MeSH) vocabulary. (several articles on the subject)

 

Commentary from the author on Twitter

 


Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.

12 Jan, 2022 | 09:09h | UTC

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

Commentaries:

Pfizer antiviral pills may be risky with other medications – NBC News

The New COVID-19 Pill, Paxlovid, Interacts with Many Medications: Cardiac Patients Take Note – The Skeptical Cardiologist

See also: What’s New in the Guidelines – NIH COVID-19 Treatment Guidelines

 


Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.

11 Jan, 2022 | 02:38h | UTC

Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 – The Lancet Public Health

News Release: Global dementia cases set to triple by 2050 unless countries address risk factors – The Lancet

Commentaries:

Forecasting the prevalence of dementia – The Lancet Public Health

Dementia cases expected to almost triple across the world by 2050 – BBC

Number of adults with dementia to exceed 150m by 2050, study finds – The Guardian

 

Commentary on Twitter (thread – click for more)

 


AAN Guideline: Oral and topical treatment of painful diabetic polyneuropathy.

8 Jan, 2022 | 23:18h | UTC

Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee – Neurology

News Release: AAN Issues Guideline for Treatment of Painful Diabetic Neuropathy – American Academy of Neurology

 


RCT: In older patients undergoing hip fracture surgery, regional anesthesia did not reduce the incidence of postoperative delirium compared to general anesthesia.

8 Jan, 2022 | 23:09h | UTC

Effect of Regional vs General Anesthesia on Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery: The RAGA Randomized Trial – JAMA (link to abstract – $ for full-text)

Commentary: China-wide study will boost understanding of fatal surgical complication – University of Birmingham

Related:

RCT: Spinal Anesthesia not Superior to General Anesthesia for Hip Surgery in Older Adults.

RCT: Similar long-term survival after combined epidural–general anesthesia vs. general anesthesia alone.

Delirium in Older Patients after Combined Epidural–General Anesthesia or General Anesthesia for Major Surgery: A Randomized Trial – Anesthesiology

 


In a large retrospective cohort study of patients with atrial fibrillation 65 years or older, treatment with rivaroxaban compared with apixaban was associated with increased risk of major ischemic or hemorrhagic events.

8 Jan, 2022 | 22:37h | UTC

Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation – JAMA

Commentary: Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study – TCTMD

Related:

Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation – American Journal of Medicine

Observational Study Suggests Apixaban May Be a Better Choice than Rivaroxaban for Patients with Atrial Fibrillation

 


Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban.

8 Jan, 2022 | 22:36h | UTC

Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data – Annals of Internal Medicine

Commentaries:

Apixaban shows superior effectiveness, safety compared to rivaroxaban – ACP Internist

Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban – American College of Cardiology

 


Prevention of Chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes.

17 Dec, 2021 | 08:32h | UTC

Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes – Drugs & Aging (if the link is paywalled, try this one)

 


Management of Hip Fractures in Older Adults: Evidence-Based Clinical Practice Guideline.

16 Dec, 2021 | 09:42h | UTC

Management of Hip Fractures in Older Adults Evidence-Based Clinical Practice Guideline – American Academy of Orthopaedic Surgeons

Summary: Management of Hip Fractures in Older Adults – American Academy of Orthopaedic Surgeons

News Release: AAOS Updates Clinical Practice Guideline for Management of Hip Fractures in Older Adults

 


Expert consensus and practical guidance: A global perspective on improving patient care in uncomplicated urinary tract infection.

15 Dec, 2021 | 08:33h | UTC

A global perspective on improving patient care in uncomplicated urinary tract infection: Expert consensus and practical guidance – Journal of Global Antimicrobial Resistance

 


Proposed subtypes of long-Covid and their respective potential therapies.

14 Dec, 2021 | 09:49h | UTC

Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies – Reviews in Medical Virology

Related:

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

 


Large observational study in Israel showed a third dose (booster) of the Pfizer–BioNTech vaccine had 90% effectiveness at preventing death due to Covid-19 compared to a two-dose regimen.

9 Dec, 2021 | 10:35h | UTC

BNT162b2 Vaccine Booster and Mortality Due to Covid-19 – New England Journal of Medicine

Editorial: Booster Doses and Prioritizing Lives Saved

 


Review: Neuropsychiatric assessment and management of the ICU survivor.

10 Dec, 2021 | 10:01h | UTC

Neuropsychiatric assessment and management of the ICU survivor – Cleveland Clinic Journal of Medicine

 


Review: Current issues in the use of opioids for the management of postoperative pain.

9 Dec, 2021 | 10:18h | UTC

Current Issues in the Use of Opioids for the Management of Postoperative Pain: A Review – JAMA Surgery (free for a limited period)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.